Circumvention of TKI resistance with HDAC inhibitors in lung cancer

被引：0
|
作者：
Yano, Seiji [1 ]
机构：
[1] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 9201192, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JS1-5
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer
    Zhu, Lucheng
    Wu, Kan
    Ma, Shenglin
    Zhang, Shirong
    TUMORI, 2015, 101 (03) : 257 - 262
  • [22] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [23] Prediction of TKI resistance in lung cancer through the experimental models and in silico simulations
    Katayama, Ryohei
    Fujita, Naoya
    CANCER SCIENCE, 2018, 109 : 1147 - 1147
  • [24] HDAC inhibitors and the mechanism of resistance in colorectal cancer: RAS and MYC - the partners in crime
    Ispasanie, Sylvia S.
    Boehme, Lena
    Eilers, Martin
    Brummer, Tilman
    Klotz-Noack, Kathleen
    Kuhn, Natalia
    Gastl, Bastian
    Sers, Christine
    CANCER RESEARCH, 2017, 77
  • [25] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [26] EGFR-TKI FOR LUNG CANCER
    Bai, Chunxue
    RESPIROLOGY, 2010, 15 : 23 - 23
  • [27] HDACs and HDAC inhibitors in colon cancer
    Mariadason, John M.
    EPIGENETICS, 2008, 3 (01) : 28 - 37
  • [28] MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
    Qin, Kang
    Hong, Lingzhi
    Zhang, Jianjun
    Le, Xiuning
    CANCERS, 2023, 15 (03)
  • [29] THERAPEUTIC STRATEGIES FOR OVERCOMING RESISTANCE TO EGFR-TKI AND ALK-TKI BY INHIBITION OF Hsp90 OR HDAC
    Takeuchi, Shinji
    Yano, Seiji
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] Bombesin/GRP receptor antagonists and HDAC inhibitors are synergistic at inhibiting lung cancer proliferation
    Moody, TW
    Nakagawa, T
    Kang, Y
    Jakowlew, S
    Chan, D
    Jensen, RT
    NEUROPEPTIDES, 2006, 40 (02) : 157 - 157
12345